Im­munother­a­py biotech rais­es $37M from back­ers like Pfiz­er, Take­da, BMS

Im­munother­a­py biotech EvolveIm­mune Ther­a­peu­tics raised $37 mil­lion in a fi­nanc­ing round, backed by big names like Pfiz­er and its newest in­vestor, Bris­tol My­ers Squibb.

EvolveIm­mune said it will use the funds to ad­vance its lead T cell en­gager pro­gram, called EV-104, through pre­clin­i­cal stud­ies and in­to hu­mans in sol­id tu­mors. Its first-in-hu­man clin­i­cal tri­als are ex­pect­ed to start in 2024. EV-104 was cre­at­ed us­ing the com­pa­ny’s cos­tim­u­la­to­ry T cell en­gager plat­form, dubbed EVOLVE. The com­pa­ny un­veiled ear­ly da­ta for the can­di­date in April, where it matched the as­set against a CD3 bis­pe­cif­ic an­ti­body.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER